Immunotoxins for targeted cancer therapy

Advanced Drug Delivery Reviews

Volumn 31, Issue 1-2, 1998, Pages 53-88

  Kreitman, Robert J ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Diphtheria toxin; Fusion protein; Fv; Gelonin; Immunoconjugates; Interleukin; Monoclonal antibody; Pseudomonas exotoxin; Ricin; Saporin

Indexed keywords

CELLS; MONOCLONAL ANTIBODIES; ONCOLOGY; TOXICITY;

IMMUNOTOXINS;

CONTROLLED DRUG DELIVERY;

ABRIN; BACTERIAL TOXIN; CD19 ANTIGEN; CD22 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CYTOKINE; DIPHTHERIA TOXIN; GELONIN; GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; IMMUNOTOXIN; INTERLEUKIN 2 RECEPTOR; LIGAND; MONOCLONAL ANTIBODY; PLANT TOXIN; POKEWEED ANTIVIRUS PROTEIN; PSEUDOMONAS EXOTOXIN; RICIN; SAPORIN; TUMOR ANTIGEN;

ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLON CANCER; DISULFIDE BOND; HUMAN; LIGAND BINDING; LUNG CANCER; LYMPHOMA; MELANOMA; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TARGET CELL;

EID: 0032489877     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00094-X     Document Type: Review

References (430)

1. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics, 1997. CA-A Cancer J. Clin. 47:1997;5-27.
2. Yamaizumi M., Mekada E., Uchida T., Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell. 15:1978;245-250.
3. Eiklid K., Olsnes S., Pihl A. Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp. Cell Res. 126:1980;321-326.
4. Endo Y., Mitsui K., Motizuki M., Tsurugi K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. J. Biol. Chem. 262:1987;5908-5912.
5. Zamboni M., Brigotti M., Rambelli F., Montanaro L., Sperti S. High pressure liquid chromatographic and fluorimetric methods for the determination of adenine released from ribosomes by ricin and gelonin. Biochem. J. 259:1989;639-643.
6. Bergamaschi G., Perfetti V., Tonon L., Novella A., Lucotti C., Danova M., Glennie M.J., Merlini G., Cazzola M. Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. Br. J. Haematol. 93:1996;789-794.
7. Manske J.M., Buchsbaum D.J., Vallera D.A. The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins. J. Immunol. 142:1989;1755-1766.
8. Simpson J.C., Dascher C., Roberts L.M., Lord J.M., Balch W.E. Ricin cytotoxicity is sensitive to recycling between the endoplasmic reticulum and the Golgi complex. J. Biol. Chem. 270:1995;20078-20083.
9. Sandvig K., VanDeurs B. Endocytosis, intracellular transport, and cytotoxic action of shiga toxin and ricin. Physiol. Rev. 76:1996;949-966.
10. Krolick K.A., Villemez C., Isakson P., Uhr J.W., Vitetta E.S. Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. Proc. Natl. Acad. Sci. USA. 77:1980;5419-5423.
11. Thorpe P.E., Cumber A.J., Williams N., Edwards D.C., Ross W.C., Davies A.J. Abrogation of the non-specific toxicity of abrin conjugated to anti-lymphocyte globulin. Clin. Exp. Immunol. 43:1981;195-200.
12. Fulton R.J., Uhr J.W., Vitetta E.S. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain. Cancer Res. 48:1988;2626-2631.
13. Fulton R.J., Tucker T.F., Vitetta E.S., Uhr J.W. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization. Cancer Res. 48:1988;2618-2625.
14. Bourrie B.J., Casellas P., Blythman H.E., Jansen F.K. Study of the plasma clearance of antibody-ricin-A-chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin. Eur. J. Biochem. 155:1986;1-10.
15. Gregg E.O., Bridges S.H., Youle R.J., Longo D.L., Houston L.L., Glennie M.J., Stevenson F.K., Green I. Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia. J. Immunol. 138:1987;4502-4508.
16. Ramakrishnan S., Bjorn M.J., Houston L.L. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds. Cancer Res. 49:1989;613-617.
17. Blakey D.C., Watson G.J., Knowles P.P., Thorpe P.E. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. Cancer Res. 47:1987;947-952.
18. Thorpe P.E., Wallace P.M., Knowles P.P., Relf M.G., Brown A.N., Watson G.J., Knyba R.E., Wawrzynczak E.J., Blakey D.C. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res. 47:1987;5924-5931.
19. Thorpe P.E., Wallace P.M., Knowles P.P., Relf M.G., Brown A.N., Watson G.J., Blakey D.C., Newell D.R. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res. 48:1988;6396-6403.
20. Lambert J.M., McIntyre G., Gauthier M.N., Zullo D., Rao V., Steeves R.M., Goldmacher V.S., Blattler W.A. The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. Biochemistry. 30:1991;3234-3247.
21. Lambert J.M., Goldmacher V.S., Collinson A.R., Nadler L.M., Blattler W.A. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res. 51:1991;6236-6242.
22. Mohanraj D., Ramakrishnan S. Cytotoxic effects of ricin without an interchain disulfide bond: genetic modification and chemical crosslinking studies. Biochim. Biophys. Acta. 1243:1995;399-406.
23. Frankel A.E., Burbage C., Fu T., Tagge E., Chandler J., Willingham M.C. Ricin toxin contains at least three galactose-binding sites located in B chain subdomains 1 alpha, 1 beta, and 2 gamma. Biochemistry. 35:1996;14749-14756.
24. Frankel A.E., Burbage C., Fu T., Tagge E., Chandler J., Willingham M. Characterization of a ricin fusion toxin targeted to the interleukin-2 receptor. Protein Eng. 9:1996;913-919.
25. Frankel A., Tagge E., Chandler J., Burbage C., Hancock G., Vesely J., Willingham M. IL2-ricin fusion toxin is selectively cytotoxic in vitro to IL2 receptor-bearing tumor cells. Bioconjug. Chem. 6:1995;666-672.
26. Krek C.E., Ladino C.A., Goldmacher V.S., Blattler W.A., Guild B.C. Expression and secretion of a recombinant ricin immunotoxin from murine myeloma cells. Protein Eng. 8:1995;481-489.
27. Cook J.P., Savage P.M., Lord J.M., Roberts L.M. Biologically active interleukin-2-ricin A chain fusion proteins may require intracellular proteolytic cleavage to exhibit a cytotoxic effect. Bioconjug. Chem. 4:1993;440-447.
28. Dore J.M., Gras E., Wijdenes J. Expression and activity of a recombinant chimeric protein composed of pokeweed antiviral protein and of human interleukin-2. FEBS Lett. 402:1997;50-52.
29. Carroll S.F., Collier R.J. Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin. J. Biol. Chem. 262:1987;8707-8711.
30. Uchida T., Pappenheimer A.M. Jr., Harper A.A. Reconstitution of diphtheria toxin from two nontoxic cross-reacting mutant proteins. Science. 175:1972;901-903.
31. Uchida T., Pappenheimer A.M. Jr., Greany R. Diphtheria toxin and related proteins I. Isolation and properties of mutant proteins serologically related to diphtheria toxin. J. Biol. Chem. 248:1973;3838-3844.
32. Iglewski B.H., Liu P.V., Kabat D. Mechanism of action of Pseudomonas aeruginosa exotoxin A: adenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo. Infect. Immun. 15:1977;138-144.
33. Van Ness B.G., Howard J.B., Bodley J.W. ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products. J. Biol. Chem. 255:1980;10717-10720.
34. Phan L.D., Perentesis J.P., Bodley J.W. Saccharomyces cerevisiae elongation factor 2. Mutagenesis of the histidine precursor of diphthamide yields a functional protein that is resistant to diphtheria toxin. J. Biol. Chem. 268:1993;8665-8668.
35. Hwang J., FitzGerald D.J., Adhya S., Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell. 48:1987;129-136.
36. Allured V.S., Collier R.J., Carroll S.F., McKay D.B. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0 Angstrom resolution. Proc. Natl. Acad. Sci. USA. 83:1986;1320-1324.
37. Li M., Dyda F., Benhar I., Pastan I., Davies D.R. The crystal structure of Pseudomonas aeruginosa exotoxin domain III with nicotinamide and AMP: conformational differences with the intact exotoxin. Proc. Natl. Acad. Sci. USA. 92:1995;9308-9312.
38. Li M., Dyda F., Benhar I., Pastan I., Davies D.R. Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: implications for the activation process and for ADP ribosylation. Proc. Natl. Acad. Sci. USA. 93:1996;6902-6906.
39. Han X.Y., Galloway D.R. Active site mutations of Pseudomonas aeruginosa exotoxin A - analysis of the His(440) residue. J. Biol. Chem. 270:1995;679-684.
40. Kounnas M.Z., Morris R.E., Thompson M.R., FitzGerald D.J., Strickland D.K., Saelinger C.B. The α2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J. Biol. Chem. 267:1992;12420-12423.
41. Chiron M.F., Fryling C.M., FitzGerald D.J. Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J. Biol. Chem. 269:1994;18167-18176.
42. Fryling C., Ogata M., FitzGerald D. Characterization of a cellular protease that cleaves Pseudomonas exotoxin. Infect. Immun. 60:1992;497-502.
43. 280 generates the enzymatically active fragment which translocates to the cytosol. J. Biol. Chem. 267:1992;25396-25401.
44. Chaudhary V.K., Jinno Y., FitzGerald D., Pastan I. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc. Natl. Acad. Sci. USA. 87:1990;308-312.
45. Kreitman R.J., Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem. J. 307:1995;29-37.
46. Theuer C., Kasturi S., Pastan I. Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes. Biochemistry. 33:1994;5894-5900.
47. Theuer C.P., Buchner J., FitzGerald D., Pastan I. The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion. Proc. Natl. Acad. Sci. USA. 90:1993;7774-7778.
48. Brinkmann U., Brinkmann E., Gallo M., Pastan I. Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1. Proc. Natl. Acad. Sci. USA. 92:1995;10427-10431.
49. r~6000 region of the toxin. J. Biol. Chem. 265:1990;7331-7337.
50. Choe S., Bennett M.J., Fujii G., Curmi P.M.G., Kantardjieff K.A., Collier R.J., Eisenberg D. The crystal structure of diphtheria toxin. Science. 357:1992;216-222.
51. Papini E., Schiavo G., Tomasi M., Colombatti M., Rappuoli R., Montecucco C. Lipid interaction of diphtheria toxin and mutants with altered fragment B. 2. Hydrophobic photolabelling and cell intoxication. Eur. J. Biochem. 169:1987;637-644.
52. Moskaug J.O., Stenmark H., Olsnes S. Insertion of diphtheria toxin B-fragment into the plasma membrane at low pH. Characterization and topology of inserted regions. J. Biol. Chem. 266:1991;2652-2659.
53. Bell C.E., Eisenberg D. Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide. Biochemistry. 35:1996;1137-1149.
54. Bennett M.J., Eisenberg D. Refined structure of monomeric diphtheria toxin at 2.3 Å resolution. Protein Sci. 3:1994;1464-1475.
55. 194. J. Biol. Chem. 265:1990;20673-20677.
56. Iwamoto R., Higashiyama S., Mitamura T., Taniguchi N., Klagsbrun M., Mekada E. Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity. EMBO J. 13:1994;2322-2330.
57. vanderSpek J., Cassidy D., Genbauffe F., Huynh P.D., Murphy J.R. An intact transmembrane helix 9 is essential for the efficient delivery of the diphtheria toxin catalytic domain to the cytosol of target cells. J. Biol. Chem. 269:1994;21455-21459.
58. Zhan H., Choe S., Huynh P.D., Finkelstein A., Eisenberg D., Collier R.J. Dynamic transitions of the transmembrane domain of diphtheria toxin: disulfide trapping and fluorescence proximity studies. Biochemistry. 33:1994;11254-11263.
59. Cabiaux V., Mindell J., Collier R.J. Membrane translocation and channel-forming activities of diphtheria toxin are blocked by replacing isoleucine 364 with lysine. Infect. Immun. 61:1993;2200-2202.
60. Kaul P., Silverman J., Shen W.H., Blanke S.R., Huynh P.D., Finkelstein A., Collier R.J. Roles of Glu 349 and Asp 352 in membrane insertion and translocation by diphtheria toxin. Protein Sci. 5:1996;687-692.
61. Lemichez E., Bomsel M., Devilliers G., vanderSpek J., Murphy J.R., Lukianov E.V., Olsnes S., Boquet P. Membrane translocation of diphtheria toxin fragment A exploits early to late endosome trafficking machinery. Mol. Microbiol. 23:1997;445-457.
62. Wilson B.A., Blanke S.R., Reich K.A., Collier R.J. Active-site mutations of diphtheria toxin. Tryptophan 50 is a major determinant of NAD affinity. J. Biol. Chem. 269:1994;23296-23301.
63. Moolten F.L., Cooperband S.R. Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells. Science. 169:1970;68-70.
64. FitzGerald D.J.P., Waldmann T.A., Willingham M.C., Pastan I. Pseudomonas exotoxin-Anti-Tac: cell specific immunotoxin active against cells expressing the human T cell growth factor receptor. J. Clin. Invest. 74:1984;966-971.
65. FitzGerald D.J., Padmanabhan R., Pastan I., Willingham M.C. Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell. 32:1983;607-617.
66. Masuho Y., Hara T., Noguchi T. Preparation of a hybrid of fragment Fab′ of antibody and fragment A of diphtheria toxin and its cytotoxicity. Biochem. Biophys. Res. Commun. 90:1979;320-326.
67. Greenfield L., Johnson V.G., Youle R.J. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science. 238:1987;536-539.
68. Chaudhary V.K., Jinno Y., Gallo M.G., FitzGerald D., Pastan I. Mutagenesis of Pseudomonas exotoxin in identification of sequences responsible for the animal toxicity. J. Biol. Chem. 265:1990;16306-16310.
69. Kondo T., FitzGerald D., Chaudhary V.K., Adhya S., Pastan I. Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain. J. Biol. Chem. 263:1988;9470-9475.
70. Williams D.P., Parker K., Bacha P., Bishai W., Borowski M., Genbauffe F., Strom T.B., Murphy J.R. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng. 1:1987;493-498.
71. Siegall C.B., Chaudhary V.K., FitzGerald D.J., Pastan I. Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J. Biol. Chem. 264:1989;14256-14261.
72. Kreitman R.J., Batra J.K., Seetharam S., Chaudhary V.K., FitzGerald D.J., Pastan I. Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds. Bioconjug. Chem. 4:1993;112-120.
73. 486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J. Biol. Chem. 265:1990;11885-11889.
74. Chaudhary V.K., FitzGerald D.J., Pastan I. A proper amino terminus of diphtheria toxin is important for cytotoxicity. Biochem. Biophys. Res. Commun. 180:1991;545-551.
75. Theuer C.P., Kreitman R.J., FitzGerald D.J., Pastan I. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity. Cancer Res. 53:1993;340-347.
76. Seetharam S., Chaudhary V.K., FitzGerald D., Pastan I. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J. Biol. Chem. 266:1991;17376-17381.
77. Foon K.A., Rai K.R., Gale R.P. Chronic lymphocytic leukemia: new insights into biology and therapy. Ann. Intern. Med. 113:1990;525-539.
78. Chott A., Augustin I., Wrba F., Hanak H., Ohlinger W., Radaszkiewicz T. Peripheral T-cell lymphoma: a clinicopathologic study of 75 cases. Hum. Pathol. 21:1990;1117-1125.
79. Manske J.M., Buchsbaum D.J., Azemove S.M., Hanna D.E., Vallera D.A. Antigenic modulation by anti-CD5 immunotoxins. J. Immunol. 136:1986;4721-4728.
80. Laurent G., Kuhlein E., Casellas P., Canat X., Carayon P., Poncelet P., Correll S., Rigal F., Jansen F.K. Determination of sensitivity of fresh leukemia cells to immunotoxins. Cancer Res. 46:1986;2289-2294.
81. Kernan N.A., Knowles R.W., Burns M.J., Broxmeyer H.E., Lu L., Lee H.M., Kawahata R.T., Scannon P.J., Dupont B. Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin. J. Immunol. 133:1984;137-146.
82. Leonard J.E., Johnson D.E., Shawler D.L., Dillman R.O. Inhibition of human T-cell tumor growth by T101-ricin A-chain in an athymic mouse model. Cancer Res. 48:1988;4862-4867.
83. Kernan N.A., Byers V., Scannon P.J., Mischak R.P., Brochstein J., Flomenberg N., Dupont B., O'Reilly R.J. Treatment of steroid resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin. J. Am. Med. Assoc. 259:1988;3154-3157.
84. Hertler A.A., Schlossman D.M., Borowitz M.J., Laurent G., Jansen F.K., Schmidt C., Frankel A.E. A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. J. Biol. Response Mod. 7:1988;97-113.
85. Laurent G., Pris J., Farcet J.-P., Carayon P., Blythman H., Casellas P., Poncelet P., Jansen F.K. Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients. Blood. 67:1986;1680-1687.
86. Kohn F.R., Fishwild D.M., Kung A.H. Efficacy of an anti-CD5-ricin A chain immunoconjugate in an improved human peripheral blood lymphocyte-reconstituted severe combined immunodeficient mouse model. Int. J. Immunopharmacol. 15:1993;695-709.
87. Koehler M., Hurwitz C.A., Krance R.A., Coustan-Smith E., Williams L.L., Santana V., Ribeiro R.C., Brenner M.K., Heslop H.E. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant. 13:1994;571-575.
88. Fishwild D.M., Strand V. Administration of an anti-CD5 immunoconjugate to patients with rheumatoid arthritis: effect on peripheral blood mononuclear cells and in vitro immune function. J. Rheumatol. 21:1994;596-604.
89. Stafford F.J., Fleisher T.A., Lee G., Brown M., Strand V., Austin H.A., Balow J.E., Klippel J.H. A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus. J. Rheumatol. 21:1994;2068-2070.
90. Byers V.S., Henslee P.J., Kernan N.A., Blazar B.R., Gingrich R., Phillips G.L., LeMaistre C.F., Gilliland G., Antin J.H., Martin P.et al. Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood. 75:1990;1426-1432.
91. Phillips G.L., Nevill T.J., Spinelli J.J., Nantel S.H., Klingemann H.G., Barnett M.J., Shepherd J.D., Chan K.W., Meharchand J.M., Sutherland H.J.et al. Prophylaxis for acute graft-versus-host disease following unrelated donor bone marrow transplantation. Bone Marrow Transplant. 15:1995;213-219.
92. Siena S., Lappi D.A., Bregni M., Formosa A., Villa S., Soria M., Bonadonna G., Gianni A.M. Synthesis and characterization of an antihuman T-lymphocyte saporin immunotoxin (OKT1-SAP) with in vivo stability into nonhuman primates. Blood. 72:1988;756-765.
93. Porro G., Bolognesi A., Caretto P., Gromo G., Lento P., Mistza G., Sciumbata T., Stirpe F., Modena D. In vitro and in vivo properties of an anti-CD5-momordin immunotoxin on normal and neoplastic T lymphocytes. Cancer Immunol. Immunother. 36:1993;346-350.
94. Bernhard S.L., Better M., Fishwild D.M., Lane J.A., Orme A.E., Garrison D.A., Birr C.A., Lei S.P., Carroll S.F. Cysteine analogs of recombinant barley ribosome inactivating protein form antibody conjugates with enhanced stability and potency in vitro. Bioconjug. Chem. 5:1994;126-132.
95. Better M., Bernhard S.L., Fishwild D.M., Nolan P.A., Bauer R.J., Kung A.H., Carroll S.F. Gelonin analogs with engineered cysteine residues form antibody immunoconjugates with unique properties. J. Biol. Chem. 269:1994;9644-9650.
96. Taniguchi T., Minami Y. The IL2/IL-2 receptor system: a current overview. Cell. 73:1993;5-8.
97. Kodaka T., Uchiyama T., Ishikawa T., Kamio M., Onishi R., Itoh K., Hori T., Uchino H., Tsudo M., Araki K. Interleukin-2 receptor β-chain (p70-75) expressed on leukemic cells from adult T cell leukemia patients. Jpn. J. Cancer Res. 81:1990;902-908.
98. Yagura H., Tamaki T., Furitsu T., Tomiyama Y., Nishiura T., Tominaga N., Katagiri S., Yonezawa T., Tarui S. Demonstration of high-affinity interleukin-2 receptors on B-chronic lymphocytic leukemia cells: functional and structural characterization. Blut. 60:1990;181-186.
99. Kreitman R.J., Pastan I. Recombinant single-chain immunotoxins against T and B cell leukemias. Leuk. Lymphoma. 13:1994;1-10.
100. Robb R.J., Greene W.C., Rusk C.M. Low and high affinity cellular receptors for interleukin 2. J. Exp. Med. 160:1984;1126-1146.
101. Gazzola M., Collins N.H., Tafuri A., Keever C.A. Recombinant interleukin 3 induces interleukin 2 receptor expression on early myeloid cells in normal human bone marrow. Exp. Hematol. 20:1992;201-208.
102. Hoshino S., Oshimi K., Mizoguchi H. Interleukin-2 receptor β chain in leukemias and lymphomas. Leuk. Lymphoma. 6:1992;107-116.
103. Uchiyama T.A., Broder S., Waldmann T.A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J. Immunol. 126:1981;1393-1397.
104. Kozak R.W., Fitzgerald D.P., Atcher R.W., Goldman C.K., Nelson D.L., Gansow O.A., Pastan I., Waldmann T.A. Selective elimination in vitro of alloresponsive T cells to human transplantation antigens by toxin or radionuclide conjugated anti-IL-2 receptor (Tac) monoclonal antibody. J. Immunol. 144:1990;3417-3423.
105. Batra J.K., Jinno Y., Chaudhary V.K., Kondo T., Willingham M.C., FitzGerald D.J., Pastan I. Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA. 86:1989;8545-8549.
106. Kronke M., Depper J.M., Leonard W.J., Vitetta E.S., Waldmann T.A., Green W.C. Adult T cell leukemia: a potential target for ricin A chain immunotoxins. Blood. 65:1985;1416-1421.
107. Bacha P., Williams D.P., Waters C., Williams J.M., Murphy J.R., Strom T.B. Interleukin 2 receptor-targeted cytotoxicity: interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J. Exp. Med. 167:1988;612-622.
108. Lorberboum-Galski H., FitzGerald D., Chaudhary V., Adhya S., Pastan I. Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli. Proc. Natl. Acad. Sci. USA. 85:1988;1922-1926.
109. Lorberboum-Galski H., Kozak R.W., Waldmann T.A., Bailon P., FitzGerald D.J.P., Pastan I. Interleukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor. J. Biol. Chem. 263:1988;18650-18656.
110. Waters C.A., Schimke P.A., Snider C.E., Itoh K., Smith K.A., Nichols J.C., Strom T.B., Murphy J.R. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur. J. Immunol. 20:1990;785-791.
111. Re G.G., Waters C., Poisson L., Willingham M.C., Sugamura K., Frankel A.E. Interleukin 2 (IL-2) receptor expression and sensitivity to diphtheria fusion toxin DAB(389)IL-2 in cultured hematopoietic cells. Cancer Res. 56:1996;2590-2595.
112. 4Glu, a new chimeric protein cytotoxic to human activated T lymphocytes. J. Biol. Chem. 265:1990;16311-16317.
113. Lorberboum-Galski H., Barrett L.V., Kirkman R.L., Ogata M., Willingham M.C., FitzGerald D.J., Pastan I. Cardiac allograft survival in mice treated with IL-2-PE40. Proc. Natl. Acad. Sci. USA. 86:1989;1008-1012.
114. Lorberboum-Galski H., Lafyatis R., Case J.P., FitzGerald D., Wilder R.L., Pastan I. Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion. Int. J. Immunopharm. 13:1991;305-315.
115. Kelley V.E., Bacha P., Pankewycz O., Nichols J.C., Murphy J.R., Strom T.B. Interleukin 2-diphtheria toxin fusion protein can abolish cell-mediated immunity in vivo. Proc. Natl. Acad. Sci. USA. 85:1988;3980-3984.
116. Bacha P.A., Forte S.E., McCarthy D.M., Estis L., Yamada G., Nichols J.C. Impact of interleukin-2-receptor-targeted cytotoxins on a unique model of murine interleukin-2-receptor-expressing malignancy. Int. J. Cancer. 49:1991;96-101.
117. Mackie J.D., Pankewycz O.G., Hassarjian R., Murphy J.R., Kelley V.E., Strom T.B. Immunotherapy using interleukin-2 diphtheria toxin chimer prolongs murine allografts. Transplant Proc. 21:1989;2718-2719.
118. Kirkman R.L., Bacha P., Barrett L.V., Forte S., Murphy J.R., Strom T.B. Prolongation of cardiac allograft survival in murine recipients treated with a diphtheria toxin-related interleukin-2 fusion protein. Transplantation. 47:1989;327-330.
119. Pankewycz O., Mackie J., Hassarjian R., Murphy J.R., Strom T.B., Kelley V.E. Interleukin-2-diphtheria toxin fusion protein prolongs murine islet cell engraftment. Transplantation. 47:1989;318-322.
120. Miller D.D., Bach R.G., Tio F.O., Bailey S.R., Waters C.A., Woodworth T.G., Nichols J.C., Paige S.B., Farrar M. Interleukin-2 receptor-specific fusion toxin inhibits barotrauma-induced arterial atherosclerosis. Atherosclerosis. 126:1996;1-14.
121. Rose J.W., Lorberboum-Galski H., FitzGerald D., McCarron R., Hill K.E., Townsend J.J., Pastan I. Chimeric cytotoxin IL2-PE40 inhibits relapsing experimental allergic encephalomyelitis. J. Neuroimmunol. 32:1991;209-217.
122. Herbort C.P., Smet M.D.d., Roberge F.G., Nussenblatt R.B., FitzGerald D., Lorberboum-Galski H., Pastan I. Treatment of corneal allograft rejection with the cytotoxin IL-2-PE40. Transplantation. 52:1991;470-474.
123. Kozak R.W., Loberboum-Galski H., Jones L., Puri R.K., Willingham M.C., Malek T., FitzGerald D.J., Waldmann T.A., Pastan I. IL-2-PE40 prevents the development of tumors in mice injected with IL-2 receptor expressing EL4 transfectant tumor cells. J. Immunol. 145:1990;2766-2771.
124. Case J.P., Lorberboum-Galski H., Lafyatis R., FitzGerald D., Wilder R.L., Pastan I. Chimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthritis in rats. Proc. Natl. Acad. Sci. USA. 86:1989;287-291.
125. Hullett D.A., Landry A.S., Eckhoff D.E., Nichols J.C., Eugui E.M., Allison A.C., Sollinger H.W. DAB486-IL-2 (IL-2-toxin) in combination with low-dose RS-61443 (mycophenolate mofetil) prolongs murine thyroid allograft survival. Transplant Proc. 25:1993;756-757.
126. Puri R.K., FitzGerald D., Leland P., Kozak R.W., Pastan I. In vitro and in vivo suppression of interleukin-2-activated killer cell activity by chimeric proteins between interleukin-2 and Pseudomonas exotoxin. Cell Immunol. 143:1992;324-334.
127. Walz G., Zanker B., Brand K., Waters C., Genbauffe F., Zeldis J.B., Murphy J.R., Strom T.B. Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation. Proc. Natl. Acad. Sci. USA. 86:1989;9485-9488.
128. 486IL-2) in patient with chronic lymphocytic leukaemia. Lancet. 337:1991;1124-1125.
129. 486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood. 79:1992;2547-2554.
130. 486IL-2 in hematological cancers. Cancer Res. 53:1993;3930-3934.
131. 486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas. Leuk. Lymphoma. 11:1993;369-377.
132. Hesketh P., Caguioa P., Koh H., Dewey H., Facada A., McCaffrey R., Parker K., Nylen P., Woodworth T. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 11:1993;1682-1690.
133. Tepler I., Schwartz G., Parker K., Charette J., Kadin M.E., Woodworth T.G., Schnipper L.E. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer. 73:1994;1276-1285.
134. Platanias L.C., Ratain M.J., S O.B., Larson R.A., Vardiman J.W., Shaw J.P., Williams S.F., Baron J.M., Parker K., Woodworth T.G. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk. Lymphoma. 14:1994;257-262.
135. Cohen R., Jaffe E.S., Stetler-Stevenson M.A., Sausville E.A., DeNigris E.C., Woodworth T., Foss F.M. Bilateral adrenal hemorrhage and adrenal insufficiency in a patient with lymphomatous adrenal infiltration following administration of a fusion toxin (DAB486 interleukin-2). J. Immunother. Emphasis Tumor. Immunol. 16:1994;229-233.
136. 486IL-2 in advanced mycosis fungoides and the sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood. 84:1994;1765-1774.
137. 486IL-2 fusion toxin in refractory rheumatoid arthritis. Arthritis Rheum. 36:1993;1223-1233.
138. Moreland L.W., Sewell K.L., Trentham D.E., Bucy R.P., Sullivan W.F., Schrohenloher R.E., Shmerling R.H., Parker K.C., Swartz W.G., Woodworth T.G., Koopman W.J. Interleukin-2 diphtheria fusion protein (DAB(486)IL-2) in refractory rheumatoid arthritis: a double-blind, placebo-controlled trial with open-label extension. Arthritis Rheum. 38:1995;1177-1186.
139. Waldmann T.A., Goldman C.K., Robb R.J., Depper J.M., Leonard W.J., Sharrow S.O., Bongiovanni K.F., Korsmeyer S.J., Greene W.C. Expression of interleukin 2 receptors on activated human B cells. J. Exp. Med. 160:1984;1450-1466.
140. Huston J.S., Levinson D., Mudgett-Hunter M., Tai M.-S., Novotny J., Margolies M.N., Ridge R.J., Bruccoleri R.E., Haber E., Crea R., Oppermann H. Protein engineering of antibody binding sites: recovery of specific activity in an antidigoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA. 85:1988;5879-5883.
141. Bird R.E., Hardman K.D., Jacobson J.W., Johnson S., Kaufman B.M., Lee S.-M., Lee T., Pope S.H., Riordan G.S., Whitlow M. Single-chain antigen-binding proteins. Science. 242:1988;423-426.
142. Chaudhary V.K., Queen C., Junghans R.P., Waldmann T.A., FitzGerald D.J., Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature. 339:1989;394-397.
143. Batra J.K., FitzGerald D., Gately M., Chaudhary V.K., Pastan I. Anti-Tac(Fv)-PE40: a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells. J. Biol. Chem. 265:1990;15198-15202.
144. Kreitman R.J., Chaudhary V.K., Waldmann T., Willingham M.C., FitzGerald D.J., Pastan I. The recombinant immunotoxin anti-Tac(Fv)-Pseuodomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia. Proc. Natl. Acad. Sci. USA. 87:1990;8291-8295.
145. Kreitman R.J., Chaudhary V.K., Waldmann T.A., Hanchard B., Cranston B., FitzGerald D.J.P., Pastan I. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia. Leukemia. 7:1993;553-562.
146. Saito T., Kreitman R.J., Hanada S.-i., Makino T., Utsunomiya A., Sumizawa T., Arima T., Chang C.N., Hudson D., Pastan I., Akiyama S.-i. Cytotoxicity of recombinant Fab and Fv immunotoxins on adult T-cell leukemia lymph node and blood cells in the presence of soluble interleukin-2 receptor. Cancer Res. 54:1994;1059-1064.
147. Kiyokawa T., Shirono K., Hattori T., Nishimura H., Yamaguchi K., Nichols J.C., Strom T.B., Murphy J.R., Takatsuki K. Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Res. 49:1989;4042-4046.
148. Kreitman R.J., Bailon P., Chaudhary V.K., FitzGerald D.J.P., Pastan I. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood. 83:1994;426-434.
149. Kreitman R.J., Pastan I. Targeting Pseudomonas exotoxin to hematologic malignancies. Semin. Cancer. Biol. 6:1995;297-306.
150. Kreitman R.J., Chaudhary V.K., Kozak R.W., FitzGerald D.J.P., Waldmann T.A., Pastan I. Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia. Blood. 80:1992;2344-2352.
151. Chaudhary V.K., Gallo M.G., FitzGerald D.J., Pastan I. A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin. Proc. Natl. Acad. Sci. USA. 87:1990;9491-9494.
152. Reiter Y., Brinkmann U., Kreitman R.J., Jung S.-H., Lee B., Pastan I. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry. 33:1994;5451-5459.
153. Reiter Y., Kreitman R.J., Brinkmann U., Pastan I. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin. Int. J. Cancer. 58:1994;142-149.
154. Kreitman R.J., Chang C.N., Hudson D.V., Queen C., Bailon P., Pastan I. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model. Int. J. Cancer. 57:1994;856-864.
155. Engert A., Martin G., Amlot P., Wijdenes J., Diehl V., Thorpe P. Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice. Int. J. Cancer. 49:1991;450-456.
156. Engert A., Gottstein C., Winkler U., Amlot P., Pileri S., Diehl V., Thorpe P. Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins. Leuk. Lymphoma. 13:1994;441-448.
157. Winkler U., Gottstein C., Schon G., Kapp U., Wolf J., Hansmann M.-L., Bohlen H., Thorpe P., Diehl V., Engert A. Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins. Blood. 83:1994;466-475.
158. Engert A., Diehl V., Schnell R., Radszuhn A., Hatwig M.T., Drillich S., Schon G., Bohlen H., Tesch H., Hansmann M.L., Barth S., Schindler J., Ghetie V., Uhr J., Vitetta E. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood. 89:1997;403-410.
159. Tazzari P.L., Bolognesi A., De Totero D., Pileri S., Conte R., Wijdenes J., Herve P., Soria M., Stirpe F., Gobbi M. B-B10 (anti-CD25)-saporin immunotoxin - a possible tool in graft-versus-host disease treatment. Transplantation. 54:1992;351-356.
160. Tazzari P.L., Zhang S., Chen Q., Sforzini S., Bolognesi A., Stirpe F., Xie H., Moretta A., Ferrini S. Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation. Br. J. Cancer. 67:1993;1248-1253.
161. Tonevitskii A.G., Agapov I.I., Shamshiev A.T., Bushueva T.L., Kerner I.D., Kopp J., Pfuller U. Comparison of the activity of anti-CD25 immunotoxins based on the ricin A-subunit and a toxin from mistletoe lectin MLI. Dokl. Akad. Nauk. 339:1994;407-409.
162. Kreitman R.J., Schneider W.P., Queen C., Tsudo M., FitzGerald D.J.P., Waldmann T.A., Pastan I. Mik-β1(Fv)-PE40, a recombinant immunotoxin cytotoxic toward cells bearing the β-chain of the IL-2 receptor. J. Immunol. 149:1992;2810-2815.
163. Law C.L., Aruffo A., Chandran K.A., Doty R.T., Clark E.A. Ig domains 1 and 2 of murine CD22 constitute the ligand-binding domain and bind multiple sialylated ligands expressed on B and T cells. J. Immunol. 155:1995;3368-3376.
164. Otipoby K.L., Andersson K.B., Draves K.E., Klaus S.J., Farr A.G., Kerner J.D., Perlmutter R.M., Law C.L., Clark E.A. CD22 regulates thymus-independent responses and the lifespan of B cells. Nature. 384:1996;634-637.
165. Shen G., Li J., Ghetie M., Ghetie V., May R.D., Till M., Brown A.N., Relf M., Knowles P., Uhr J.W., Janossy G., Amlot P., Vitetta E.S., Thorpe P.E. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. Int. J. Cancer. 42:1988;792-797.
166. Ghetie M.-A., May R.D., Till M., Uhr J.W., Ghetie V., Knowles P.P., Relf M., Brown A., Wallace P.M., Janossy G., Amlot P., Vitetta E.S., Thorpe P.E. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res. 48:1988;2610-2617.
167. Ghetie M.-A., Richardson J., Tucker T., Jones D., Uhr J.W., Vitetta E.S. Antitumor activity of Fab′ and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Res. 51:1991;5876-5880.
168. Ghetie M.-A., Tucker K., Richardson J., Uhr J.W., Vitetta E.S. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood. 80:1992;2315-2320.
169. Amlot P.L., Stone M.J., Cunningham D., Fay J., Newman J., Collins R., May R., McCarthy M., Richardson J., Ghetie V., Ramilo O., Thorpe P.E., Uhr J.W., Vitetta E.S. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood. 82:1993;2624-2633.
170. Vitetta E.S., Stone M., Amlot P., Fay J., May R., Till M., Newman J., Clark P., Collins R., Cunningham D., Ghetie V., Uhr J., Thorpe P.E. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 51:1991;4052-4058.
171. Sausville E.A., Headlee D., Stetler-Stevenson M., Jaffe E.S., Solomon D., Figg W.D., Herdt J., Kopp W.C., Rager H., Steinberg S.M., Ghetie V., Schindler J., Uhr J., Wittes R.E., Vitetta E.S. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood. 85:1995;3457-3465.
172. Bonardi M.A., Bell A., French R.R., Gromo G., Hamblin T., Modena D., Tutt A.L., Glennie M.J. Initial experience in treating human lymphoma with a combination of bispecific antibody and saponin. Int. J. Cancer. 7:1992;73-77.
173. Kreitman R.J., Hansen H.J., Jones A.L., FitzGerald D.J.P., Goldenberg D.M., Pastan I. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab′ induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Res. 53:1993;819-825.
174. Mansfield E., Pastan I., FitzGerald D.J. Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies. Bioconjug. Chem. 7:1996;557-563.
175. Scheuermann R.H., Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk. Lymphoma. 18:1995;385.
176. Sato S., Steeber D.A., Tedder T.F. The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation. Proc. Natl. Acad. Sci. USA. 92:1995;11558-11562.
177. Uckun F.M., Gajl-Peczalska K.J., Kersey J.H., Houston L.L., Vallera D.A. Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia. J. Exp. Med. 163:1986;347-368.
178. Uckun F.M. Anti-CD19 immunotoxins for in vivo immunotherapy of B-lineage acute lymphoblastic leukemias. Antibody Immunoconj. Radiophar. 1:1988;247-262.
179. Uckun F.M., Manivel C., Arthur D., Chelstrom L.M., Finnegan D., Tuel-Ahlgren L., Irvin J.D., Myers D.E., Gunther R. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood. 79:1992;2201-2214.
180. Uckun F.M., Chelstrom L.M., Irvin J.D., Finnegan D., Gunther R., Young J., Kuebelbeck V., Myers D.E., Houston L.L. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia. Blood. 79:1992;2649-2661.
181. Jansen B., Uckun F.M., Jaszcz W.B., Kersey J.H. Establishment of a human t(4;11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CD19 (B43)-pokeweed antiviral protein immunotoxin. Cancer Res. 52:1992;406-412.
182. Waddick K.G., Myers D.E., Gunther R., Chelstrom L.M., Chandan-Langlie M., Irvin J.D., Tumer N., Uckun F.M. In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells. Blood. 86:1995;4228-4233.
183. Uckun F. Immunotoxins for the treatment of leukaemia. Br. J. Haematol. 85:1993;435-438.
184. Conry R.M., Khazaeli M.B., Saleh M.N., Ghetie V., Vitetta E.S., Liu T.P., LoBuglio A.F. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration. J. Immunother. 18:1995;231-241.
185. Roy D.C., Perreault C., Belanger R., Gyger M., Le Houillier C., Blattler W.A., Lambert J.M., Ritz J. Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin. J. Clin. Immunol. 15:1995;51-57.
186. Shah S.A., Lambert J.M., Goldmacher V.S., Esber H.J., Levin J.L., Chungi V., Zutshi A., Braman G.M., Ariniello P.D., Taylor J.A.et al. Evaluation of the systemic toxicity and pharmacokinetics of the immunoconjugate anti-B4-blocked ricin in non-human primates. Delivered by multiple bolus injections and by continuous infusion. Int. J. Immunopharmacol. 15:1993;723-736.
187. Shah S.A., Halloran P.M., Ferris C.A., Levine B.A., Bourret L.A., Goldmacher V.S., Blattler W.A. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res. 53:1993;1360-1367.
188. Grossbard M.L., Freedman A.S., Ritz J., Coral F., Goldmacher V.S., Eliseo L., Spector N., Dear K., Lambert J.M., Blattler W.A., Taylor J.A., Nadler L.M. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood. 79:1992;576-585.
189. Grossbard M.L., Lambert J.M., Goldmacher V.S., Spector N.L., Kinsella J., Eliseo L., Coral F., Taylor J.A., Blattler W.A., Epstein C.L., Nadler L.M. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J. Clin. Oncol. 11:1993;726-737.
190. Grossbard M.L., Gribben J.G., Freedman A.S., Lambert J.M., Kinsella J., Rabinowe S.N., Eliseo L., Taylor J.A., Blattler W.A., Epstein C.L., Nadler L.M. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood. 81:1993;2263-2271.
191. Bregni M., Siena S., Formosa A., Lappi D.A., Martineau D., Malavasi F., Dorken B., Bonadonna G., Gianni A.M. B-cell restricted saporin immunotoxins: activity against B-cell lines and chronic lymphocytic leukemia cells. Blood. 73:1989;753-762.
192. Flavell D.J., Flavell S.U., Boehm D.A., Emery L., Noss A., Ling N.R., Richardson P.R., Hardie D., Wright D.H. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours. Br. J. Cancer. 72:1995;1373-1379.
193. Flavell D.J., Boehm D.A., Emery L., Noss A., Ramsay A., Flavell S.U. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone. Int. J. Cancer. 62:1995;337-344.
194. Ramakrishnan S., Uckun F.M., Houston L.L. Anti-T cell immunotoxins containing pokeweed anti-viral protein: potential purging agents for human autologous bone marrow transplantation. J. Immunol. 135:1985;3616-3622.
195. Gunther R., Chelstrom L.M., Finnegan D., Tuel-Ahlgren L., Irvin J.D., Myers D.E., Uckun F.M. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency. Leukemia. 7:1993;298-309.
196. Fishwild D.M., Staskawicz M.O., Wu H.M., Carroli S.F. Cytotoxicity against human peripheral blood mononuclear cells and T cell lines mediated by anti-T cell immunotoxins in the absence of added potentiator. Clin. Exp. Immunol. 86:1991;506-513.
197. Vallera D.A., Burns L.J., Frankel A.E., Sicheneder A.R., Gunther R., Gajl-Peczalska K., Pennell C.A., Kersey J.H. Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies. J. Immunol. Methods. 197:1996;69-83.
198. Jansen B., Vallera D.A., Jaszcz W.B., Nguyen D., Kersey J.H. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. Cancer Res. 52:1992;1314-1321.
199. Flavell D.J., Cooper S., Okayama K., Emery L., Flavell S.U. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line. Hematol. Oncol. 13:1995;185-200.
200. Flavell D.J., Boehm D.A., Okayama K., Kohler J.A., Flavell S.U. Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers. Int. J. Cancer. 58:1994;407-414.
201. Morland B.J., Barley J., Boehm D., Flavell S.U., Ghaleb N., Kohler J.A., Okayama K., Wilkins B., Flavell D.J. Effectiveness of HB2 (anti-CD7)-saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice. Br. J. Cancer. 69:1994;279-285.
202. Youle R.J., Uckun F.M., Vallera D.A., Colombatti M. Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen. J. Immunol. 136:1986;93-98.
203. Colombatti M., Greenfield L., Youle R.J. Cloned fragment of diphtheria toxin linked to T cell-specific antibody identifies regions of B chain active in cell entry. J. Biol. Chem. 261:1986;3030-3035.
204. Neville D.M. Jr., Scharff J., Hu H.Z., Rigaut K., Shiloach J., Slingerland W., Jonker M. A new reagent for the induction of T-cell depletion, anti-CD3-CRM9. J. Immunother. Emphasis Tumor. Immunol. 19:1996;85-92.
205. Thompson J., Hu H., Scharff J., Neville D.M. Jr. An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood. J. Biol. Chem. 270:1995;28037-28041.
206. 390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3ε moiety of the T-cell receptor. Blood. 88:1996;2342-2353.
207. van Oosterhout Y.V., Preijers F.W., Wessels H.M., de Witte T. Cytotoxicity of CD3-ricin A chain immunotoxins in relation to cellular uptake and degradation kinetics. Cancer Res. 52:1992;5921-5925.
208. Filipovich A.H., Vallera D.A., Youle R.J., Haake R., Blazar B.R., Arthur D., Neville D.M.J., Ramsay N.K.C., McGlave P., Kersey J.H. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. Transplantation. 44:1987;62-69.
209. Martin P.J., Hansen J.A., Torok-Storb B., Moretti L., Press O., Storb R., Thomas E.D., Weiden P.L., Vitetta E.S. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease. Bone Marrow Transplant. 3:1988;437-444.
210. de Bruin P.C., Gruss H.J., van der Valk P., Willemze R., Meijer C.J. CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications. Leukemia. 9:1995;1620-1627.
211. Engert A., Gottstein C., Bohlen H., Winkler U., Schon G., Manske O., Schnell R., Diehl V., Thorpe P. Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice. Int. J. Cancer. 63:1995;304-309.
212. Engert A., Martin G., Pfreundschuh M., Amlot P., Hsu S.M., Diehl V., Thorpe P. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab′ fragments on solid human Hodgkin's disease tumors in mice. Cancer Res. 50:1990;2929-2935.
213. Schnell R., Linnartz C., Katouzi A.A., Schon G., Bohlen H., HornLohrens O., Parwaresch R.M., Lange H., Diehl V., Lemke H., Engert A. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Int. J. Cancer. 63:1995;238-244.
214. Pasqualucci L., Wasik M., Teicher B.A., Flenghi L., Bolognesi A., Stirpe F., Polito L., Falini B., Kadin M.E. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Blood. 85:1995;2139-2146.
215. Falini B., Bolognesi A., Flenghi L., Tazzari P.L., Broe M.K., Stein H., Durkop H., Aversa F., Corneli P., Pizzolo G., Barbabietola G., Sabattini E., Pileri S., Martelli M.F., Stirpe F. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet. 339:1992;1195-1196.
216. Sforzini S., Bolognesi A., Meazza R., Marciano S., Casalini P., Durkop H., Tazzari P.L., Stein H., Stirpe F., Ferrini S. Differential sensitivity of CD30+ neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies. Br. J. Haematol. 90:1995;572-577.
217. Bolognesi A., Tazzari P.L., Legname G., Olivieri F., Modena D., Conte R., Stirpe F. Anti-CD30 immunotoxins with native and recombinant dianthin 30. Cancer Immunol. Immunother. 40:1995;109-114.
218. Kabral A., Bradstock K.F., Grimsley P., Favaloro E.J. Immunophenotype of clonogenic cells in myeloid leukaemia. Leuk. Res. 12:1988;51-59.
219. Roy D.C., Griffin J.D., Belvin M., Blattler W.A., Lambert J.M., Ritz J. Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood. 77:1991;2404-2412.
220. Engert A., Brown A., Thorpe P. Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins. Leuk. Res. 15:1991;1079-1086.
221. La Russa V.F., Griffin J.D., Kessler S.W., Cutting M.A., Knight R.D., Blattler W.A., Lambert J.M., Wright D.G. Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures. Exp. Hematol. 20:1992;442-448.
222. McGraw K.J., Rosenblum M.G., Cheung L., Scheinberg D.A. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. Cancer Immunol. Immunother. 39:1994;367-374.
223. Xu Y., Xu Q., Rosenblum M.G., Scheinberg D.A. Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice. Leukemia. 10:1996;321-326.
224. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., Kuramoto A., Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 332:1988;83-85.
225. Siegall C.B., Schwab G., Nordan R.P., FitzGerald D.J., Pastan I. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res. 50:1990;7786-7788.
226. Siegall C.B., FitzGerald D.J., Pastan I. Cytotoxicity of IL6-PE40 and derivatives on tumor cells expressing a range of interleukin 6 receptor levels. J. Biol. Chem. 265:1990;16318-16323.
227. Siegall C.B., Nordan R.P., FitzGerald D.J., Pastan I. Cell-specific toxicity of a chimeric protein composed of interleukin-6 and Pseudomonas exotoxin (IL6-PE40) on tumor cells. Mol. Cell. Biol. 10:1990;2443-2447.
228. Siegall C.B., Kreitman R.J., FitzGerald D.J., Pastan I. Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice. Cancer Res. 51:1991;2831-2836.
229. Rozemuller H., Rombouts W.J.C., Touw I.P., FitzGerald D.J.P., Kreitman R.J., Pastan I., Hagenbeek A., Martens A.C.M. Treatment of acute myelocytic leukemia with interleukin-6 Pseudomonas exotoxin fusion protein in a rat leukemia model. Leukemia. 10:1996;1796-1803.
230. Chadwick D.E., Jean L.F., Jamal N., Messner H.A., Murphy J.R., Minden M.D. Differential sensitivity of human myeloma cell lines and normal bone marrow colony forming cells to a recombinant diphtheria toxin-interleukin 6 fusion protein. Br. J. Haematol. 85:1993;25-36.
231. Jean L.-F.L., Murphy J.R. Diphtheria toxin receptor-binding domain substitution with interleukin-6: genetic construction and interleukin 6 receptor-specific action of a diphtheria toxin-related interleukin 6 fusion protein. Protein Eng. 4:1991;989-994.
232. Huang Y., Burrows F.J., Vitetta E.S. Cytotoxicity of a novel anti-ICAM-1 immunotoxin on human myeloma cell lines. Hybridoma. 12:1993;661-675.
233. Huang Y.W., Richardson J.A., Vitetta E.S. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. Cancer Res. 55:1995;610-616.
234. Lazzaro G.E., Meyer B.F., Willis J.I., Erber W.N., Herrmann R.P., Davies J.M. The synthesis of a peanut agglutinin-ricin A chain conjugate: potential as an in vitro purging agent for autologous bone marrow in multiple myeloma. Exp. Hematol. 23:1995;1347-1352.
235. Vooijs W.C., Post J., Wijdenes J., Schuurman H.J., Bolognesi A., Polito L., Stirpe F., Bast E.J., de Gast G.C. Efficacy and toxicity of plasma-cell-reactive monoclonal antibodies B-B2 and B-B4 and their immunotoxins. Cancer Immunol. Immunother. 42:1996;319-328.
236. Morisaki T., Yuzuki D.H., Lin R.T., Foshag L.J., Morton D.L., Hoon D.S.B. Interleukin 4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin 4. Cancer Res. 52:1992;6059-6065.
237. Topp M.S., Koenigsmann M., Anthony M., Oberberg D., Eitelbach F., Marschall Z.v., Notter M., Reufi B., Stein H., Thiel E., Berdel W.E. Recombinant human interleukin-4 inhibits growth of some human lung tumor cell lines in vitro and in vivo. Blood. 82:1993;2837-2844.
238. Toi M., Bicknell R., Harris A.L. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res. 52:1992;275-279.
239. Hoon D.S.B., Banez M., Okun E., Morton D.L., Irie R.F. Modulation of human melanoma cells by interleukin-4 and in combination with γ-interferon or α-tumor necrosis factor. Cancer Res. 51:1991;2002-2008.
240. Obiri N.I., Hillman G.G., Haas G.P., Sud S., Puri R.K. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J. Clin. Invest. 91:1993;88-93.
241. Obiri N.I., Siegel J.P., Varricchio F., Puri R.K. Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin. Exp. Immunol. 95:1994;148-155.
242. Puri R.K., Debinski W., Obiri N., Kreitman R., Pastan I. Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin. Cell. Immunol. 154:1994;369-379.
243. Varricchio F., Obiri N.I., Haas G.P., Puri R.K. Immunostaining of interleukin-4 receptor on human renal cell carcinoma. Lymphokine Cytokine Res. 12:1993;465-469.
244. Puri R.K., Leland P., Kreitman R.J., Pastan I. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int. J. Cancer. 58:1994;574-581.
245. Mori N., Yamashita U., Tanaka Y., Nakata K., Oda S., Morimoto I., Eto S. Interleukin-4 induces proliferation of adult T-cell leukemia cells. Eur. J. Haematol. 50:1993;133-140.
246. Mori N., Shirakawa F., Murakami S., Oda S., Eto S. Inhibitory effect of interleukin 4 on production of interleukin 6 by adult T-cell leukemia cells. Cancer Res. 53:1993;4643-4647.
247. Debinski W., Puri R.K., Kreitman R.J., Pastan I. A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin. J. Biol. Chem. 268:1993;14065-14070.
248. Debinski W., Puri R.K., Pastan I. Interleukin-4 receptors expressed on tumors may serve as a target for anticancer therapy using chimeric Pseudomonas exotoxin. Int. J. Cancer. 58:1994;744-748.
249. Puri R.K., Mehrotra P.T., Leland P., Kreitman R.J., Siegel J.P., Pastan I. A chimeric protein comprised of IL-4 and Pseudomonas exotoxin is cytotoxic for activated human lymphocytes. J. Immunol. 152:1994;3693-3700.
250. 389IL-4. J. Allergy Clin. Immunol. 95:1995;893-900.
251. Le H.V., Seelig G.F., Syto R., Ramanathan L., Windsor W.T., Borkowski D., Trotta P.P. Selective proteolytic cleavage of recombinant human interleukin 4. Evidence for a critical role of the C-terminus. Biochemistry. 30:1991;9576-9582.
252. Ramanathan L., Ingram R., Sullivan L., Greenberg R., Reim R., Trotta P.P., Le H.V. Immunochemical mapping of domains in human interleukin 4 recognized by neutralizing monoclonal antibodies. Biochemistry. 32:1993;3549-3556.
253. Powers R., Garrett D.S., March C.J., Frieden E.A., Gronenborn A.M., Clore G.M. Three-dimensional solution structure of human interleukin-4 by multidimensional heteronuclear magnetic resonance spectroscopy. Science. 256:1992;1673-1677.
254. Powers R., Garrett D.S., March C.J., Frieden E.A., Gronenborn A.M., Clore G.M. The high-resolution, three-dimensional solution structure of human interleukin-4 determined by multidimensional heteronuclear magnetic resonance spectroscopy. Biochemistry. 32:1993;6744-6762.
255. Morrison B.W., Leder P. A receptor binding domain of mouse interleukin-4 defined by a solid-phase binding assay and in vitro mutagenesis. J. Biol. Chem. 267:1992;11957-11963.
256. Walter M.R., Cook W.J., Zhao B.G., Cameron R.P. Jr., Ealick S.E., Walter R.L. Jr., Reichert P., Nagabhushan T.L., Trotta P.P., Bugg C.E. Crystal structure of recombinant human interleukin-4. J. Biol. Chem. 267:1992;20371-20376.
257. Kreitman R.J., Puri R.K., Pastan I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc. Natl. Acad. Sci. USA. 91:1994;6889-6893.
258. Kreitman R.J., Puri R.K., Leland P., Lee B., Pastan I. Site-specific conjugation to interleukin 4 containing mutated cysteine residues produces interleukin 4-toxin conjugates with improved binding and activity. Biochemistry. 33:1994;11637-11644.
259. Kreitman R.J., Puri R.K., Pastan I. Increased antitumor activity of a circularly permuted Interleukin 4-toxin in mice with Interleukin 4-receptor-bearing human carcinoma. Cancer Res. 55:1995;3357-3363.
260. Puri R.K., Hoon D.S., Leland P., Snoy P., Rand R.W., Pastan I., Kreitman R.J. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res. 56:1996;5631-5637.
261. Muirhead M., Martin P.J., Torok-Storb B., Uhr J.W., Vitetta E.S. Use of an antibody-ricin A-chain conjugate to delete neoplastic B cells from human bone marrow. Blood. 62:1983;327-332.
262. Bregni M., De Fabritiis P., Raso V., Greenberger J., Lipton J., Nadler L., Rothstein L., Ritz J., Bast R.C. Jr. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates. Cancer Res. 46:1986;1208-1213.
263. Bregni M., Lappi D.A., Siena S., Formosa A., Villa S., Soria M., Bonadonna G., Gianni A.M. Activity of a monoclonal antibody-saporin-6 conjugate against B-lymphoma cells. J. Natl. Cancer Inst. 80:1988;511-517.
264. + bone marrow cells, differentiating monomyeloid progenitors, and mature blood cell subsets. Blood. 84:1994;764-774.
265. Chiba S., Shibuya K., Piao Y., Tojo A., Sasaki N., Matsuki S., Miyagawa K., Miyazono K., Takaku F. Identification and cellular distribution of distinct proteins forming human GM-CSF receptor. Cell Regul. 1:1990;327-335.
266. Berdel W.E., Danhauser-Riedl S., Steinhauser G., Winton E.F. Various hematopoietic growth factors (interleukin-3, GM-CSF, G-CSF) stimulate clonal growth of non-hematopoietic tumor cells. Blood. 73:1989;80-83.
267. Baldwin G.C., Gasson J.C., Kaufman S.E., Quan S.G., Williams R.E., Avalos B.R., Gazdar A.F., Golde D.W., DiPersio J.F. Non-hematopoietic tumor cells express functional GM-CSF receptors. Blood. 73:1989;1033-1037.
268. Dippold W.G., Klingel R., Kerlin M., Schwaeble W., Buschenfelde K.M.Z. Stimulation of pancreas and gastric carcinoma cell growth by interleukin 3 and granulocyte-macrophage colony stimulating factor. Gastroenterology. 100:1991;1338-1344.
269. Hirsch T., Eggstein S., Frank S., Farthmann E.H., Specht B.v. Expression of GM-CSF and a functional GM-CSF receptor in the human colon carcinoma line SW403. Biochem. Biophys. Res. Commun. 217:1995;138-143.
270. Tojo A., Oshima Y. Targeted toxin therapy in the treatment of leukemia. Rinsho Ketsueki. 36:1995;578-581.
271. Chadwick D.E., Williams D.P., Niho Y., Murphy J.R., Minden M.D. Cytotoxicity of a recombinant diphtheria toxin-granulocyte colony-stimulating factor fusion protein on human leukemic blast cells. Leuk. Lymphoma. 11:1993;249-262.
272. R.J. Kreitman, I. Pastan, Recombinant toxins containing human GM-CSF and either Pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells, Blood (1997) in press.
273. Perentesis J.P., Waddick K.G., Bendel A.E., Shao Y., Warman B.E., Chandan-Langlie M., Uckun F.M. Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor. Clin. Cancer Res. 3:1997;347-355.
274. Press O.W., Martin P.J., Thorpe P.E., Vitetta E.S. Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. J. Immunol. 141:1988;4410-4417.
275. Tazzari P.L., Bolognesi A., De Totero D., Lemoli R.M., Fortuna A., Conte R., Crumpton M.J., Stirpe F. Immunotoxins containing saporin linked to different CD2 monoclonal antibodies: in vitro evaluation. Br. J. Haematol. 86:1994;97-105.
276. Collinson A.R., Lambert J.M., Liu Y., C O.D., Shah S.A., Rasmussen R.A., Goldmacher V.S. Anti-CD6-blocked ricin: an anti-pan T-cell immunotoxin. Int. J. Immunopharmacol. 16:1994;37-49.
277. Rasmussen R.A., Counts S.L., Lambert J.M., Collinson A.R. Blocked ricin-conjugated T cell immunotoxins: effect of anti-CD6-blocked ricin on normal T cell function. Cancer Immunol. Immunother. 35:1992;355-363.
278. Hara H., Luo Y., Haruta Y., Seon B.K. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6. Cancer Res. 48:1988;4673-4680.
279. Schnell R., Katouzi A.A., Linnartz C., Schoen G., Drillich S., Hansmann M.L., Schiefer D., Barth S., Zangemeister-Wittke U., Stahel R.A., Diehl V., Engert A. Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice. Int. J. Cancer. 66:1996;526-531.
280. Uckun F.M., Gajl-Peczalska K., Myers D.E., Jaszcz W., Haissig S., Ledbetter J.A. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood. 76:1990;2449-2456.
281. Francisco J.A., Gilliland L.K., Stebbins M.R., Norris N.A., Ledbetter J.A., Siegall C.B. Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen. Cancer Res. 55:1995;3099-3104.
282. Myers D.E., Uckun F.M. An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia. Leuk. Lymphoma. 18:1995;119-122.
283. Yokota S., Okazaki M., Yoshida M., Seon B.K. Biodistribution and in vivo antitumor efficacy of the systemically administered anti-human T-leukemia immunotoxins and potentiation of their efficacy by alpha-interferon. Leuk. Res. 17:1993;69-79.
284. Hara H., Seon B.K. Complete suppression of in vivo growth of human leukemia cells by specific immunotoxins: nude mouse models. Proc. Natl. Acad. Sci. USA. 84:1987;3390-3394.
285. Seon B.K. Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies. Cancer Res. 44:1984;259-264.
286. Wiels J., Junqua S., Dujardin P., Le Pecq J.B., Tursz T. Properties of immunotoxins against a glycolipid antigen associated with Burkitt's lymphoma. Cancer Res. 44:1984;129-133.
287. Demur C., Derocq J.M., Poncelet P., Chiron M., Roubinet F., Jaffrezou J.P., Bordier C., Laurent G. Effects of an anti HLA-DR immunotoxin on leukaemia cells and hematopoietic progenitors. Leuk. Res. 13:1989;1047-1054.
288. Tecce R., Fraioli R., De Fabritiis P., Sandrelli A., Savarese A., Santoro L., Cuomo M., Natali P.G. Production and characterization of two immunotoxins specific for M5b ANLL leukaemia. Int. J. Cancer. 49:1991;310-316.
289. Poccia F., Piselli P., Di Cesare S., Bach S., Colizzi V., Mattei M., Bolognesi A., Stirpe F. Recognition and killing of tumour cells expressing heat shock protein 65 kD with immunotoxins containing saporin. Br. J. Cancer. 66:1992;427-432.
290. Klimka A., Barth S., Drillich S., Wels W., Snick J.v., Renauld J., Tesch H., Bohlen H., Diehl V., Engert A. A deletion mutant of Pseudomonas exotoxin A fused to recombinant human interleukin-9 (rhIL-9-ETA′) shows specific cytotoxicity against IL-9-expressing cell lines. Cytokines Mol. Ther. 2:1996;139-146.
291. Faguet G.B., Agee J.F. Four ricin chain A-based immunotoxins directed against the common chronic lymphocytic leukemia antigen: in vitro characterization. Blood. 82:1993;536-543.
292. Jain R.K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst. 81:1989;570-576.
293. Trowbridge I.S., Domingo D.L. Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells. Nature. 294:1981;171-173.
294. Griffin T.W., Pagnini P.G., McGrath J.J., McCann J.C., Houston L.L. In vitro cytotoxicity of recombinant ricin A chain-antitransferrin receptor immunotoxin against human adenocarcinomas of the colon and pancreas. J. Biol. Response Mod. 7:1988;559-567.
295. Griffin T.W., Richardson C., Houston L.L., LePage D., Bogden A., Raso V. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma. Cancer Res. 47:1987;4266-4270.
296. Martell L.A., Agrawal A., Ross D.A., Muraszko K.M. Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res. 53:1993;1348-1353.
297. FitzGerald D.J., Willingham M.C., Pastan I. Antitumor effects of an immunotoxin made with Pseudomonas exotoxin in a nude mouse model of human ovarian cancer. Proc. Natl. Acad. Sci. USA. 83:1986;6627-6630.
298. Debinski W., Pastan I. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent. Cancer Res. 52:1992;5379-5385.
299. Batra J.K., FitzGerald D.J., Chaudhary V.K., Pastan I. Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: Anti-TFR(Fv)-PE40 and DT388-Anti-TFR(Fv). Mol. Cell. Biol. 11:1991;2200-2205.
300. Hall W.A., Myklebust A., Godal A., Nesland J.M., Fodstad O. In vivo efficacy of intrathecal transferrin-Pseudomonas exotoxin A immunotoxin against LOX melanoma. Neurosurgery. 34:1994;649-656.
301. Muraszko K., Sung C., Walbridge S., Greenfield L., Dedrick R.L., Oldfield E.H., Youle R.J. Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents. Cancer Res. 53:1993;3752-3757.
302. Johnson V.G., Wrobel C., Wilson D., Zovickian J., Greenfield L., Oldfield E.H., Youle R. Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J. Neurosurg. 70:1989;240-248.
303. Zovickian J., Youle R.J. Efficacy of intrathecal immunotoxin therapy in an animal model of leptomeningeal neoplasia. J. Neurosurg. 68:1988;767-774.
304. Youle R.J. Immunotoxins for central nervous system malignancy. Semin. Cancer Biol. 7:1996;65-70.
305. Riedel C.J., Muraszko K.M., Youle R.J. Diphtheria toxin mutant selectively kills cerebellar Purkinje neurons. Proc. Natl. Acad. Sci. USA. 87:1990;5051-5055.
306. Cawley D.B., Herschman H.R., Gilliland D.G., Collier R.J. Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic. Cell. 22:1980;563-570.
307. Masui H., Kamrath H., Apell G., Houston L.L., Mendelsohn J. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Cancer Res. 49:1989;3482-3488.
308. Taetle R., Honeysett J.M., Houston L.L. Effects of anti-epidermal growth factor (EGF) receptor antibodies and an anti-EGF receptor recombinant-ricin A chain immunoconjugate on growth of human cells. J. Natl. Cancer Inst. 80:1988;1053-1059.
309. Hirota N., Ueda M., Ozawa S., Abe O., Shimizu N. Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody. Cancer Res. 49:1989;7106-7109.
310. Ozawa S., Ueda M., Ando N., Abe O., Minoshima S., Shimizu N. Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor. Int. J. Cancer. 43:1989;152-157.
311. Real F.X., Rettig W.J., Chesa P.G., Melamed M.R., Old L.J., Mendelsohn J. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res. 46:1986;4726-4731.
312. Hendler F.J., Ozanne B.W. Human squamous cell lung cancers express increased epidermal growth factor receptors. J. Clin. Invest. 74:1984;647-651.
313. Jones N.R., Rossi M.L., Gregoriou M., Hughes J.T. Investigation of the expression of epidermal growth factor receptor and blood group A antigen in 110 human gliomas. Neuropathol. Appl. Neurobiol. 16:1990;185-192.
314. Jones N.R., Rossi M.L., Gregoriou M., Hughes J.T. Epidermal growth factor receptor expression in 72 meningiomas. Cancer. 66:1990;152-155.
315. Reynolds R.K., Talavera F., Roberts J.A., Hopkins M.P., Menon K.M. Characterization of epidermal growth factor receptor in normal and neoplastic human endometrium. Cancer. 66:1990;1967-1974.
316. Chaudhary V.K., FitzGerald D.J., Adhya S., Pastan I. Activity of a recombinant fusion protein between transforming growth factor type α and Pseudomonas toxin. Proc. Natl. Acad. Sci. USA. 84:1987;4538-4542.
317. Siegall C.B., Xu Y.-h., Chaudhary V.K., Adhya S., FitzGerald D., Pastan I. Cytotoxic activities of a fusion protein comprised of TGFα and Pseudomonas exotoxin. FASEB J. 3:1989;2647-2652.
318. Baldwin R.L., Kobrin M.S., Tran T., Pastan I., Korc M. Cytotoxic effects of TGF-alpha-Pseudomonas exotoxin A fusion protein in human pancreatic carcinoma cells. Pancreas. 13:1996;16-21.
319. Kunwar S., Pai L.H., Pastan I. Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells. J. Neurosurg. 79:1993;569-576.
320. Kameyama S., Kawamata H., Pastan I., Oyasu R. Cytotoxic effect of a fusion protein from transforming growth factor alpha and Pseudomonas exotoxin on rat and human bladder carcinoma cells in vitro. J. Cancer Res. Clin. Oncol. 120:1994;507-512.
321. Epstein S.E., Siegall C.B., Biro S., Fu Y.M., FitzGerald D., Pastan I. Cytotoxic effects of a recombinant chimeric toxin on rapidly proliferating vascular smooth muscle cells (see comments). Circulation. 84:1991;778-787.
322. Draoui M., Siegall C.B., FitzGerald D., Pastan I., Moody T.W. TGF alpha-PE40 inhibits non-small cell lung cancer growth. Life Sci. 54:1994;445-453.
323. Phillips P.C., Levow C., Catterall M., Colvin O.M., Pastan I., Brem H. Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res. 54:1994;1008-1015.
324. Pai L.H., Gallo M.G., FitzGerald D.J., Pastan I. Antitumor activity of a transforming growth factor α-Pseudomonas exotoxin fusion protein (TGF-α-PE40). Cancer Res. 51:1991;2808-2812.
325. Heimbrook D.C., Stirdivant S.M., Ahern J.D., Balishin N.L., Patrick D.R., Edwards G.M., Defeo-Jones D., FitzGerald D.J., Pastan I., Oliff A. Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts. Proc. Natl. Acad. Sci. USA. 87:1990;4697-4701.
326. Edwards G.M., DeFeo-Jones D., Tai J.Y., Vuocolo G.A., Patrick D.R., Heimbrook D.C., Oliff A. Epidermal growth factor receptor binding is affected by structural determinants in the toxin domain of transforming growth factor-alpha-Pseudomonas exotoxin fusion proteins. Mol. Cell. Biol. 9:1989;2860-2867.
327. Goldberg M.R., Heimbrook D.C., Russo P., Sarosdy M.F., Greenberg R.E., Giantonio B.J., Linehan W.M., Walther M., Fisher H.A.G., Messing E., Crawford E.D., Oliff A.I., Pastan I.H. Phase I clinical study of recombinant oncotoxin TP40 in superficial bladder cancer. Clin. Cancer Res. 1:1995;57-61.
328. Kreitman R.J., Chaudhary V.K., Siegall C.B., FitzGerald D.J., Pastan I. Rational design of a chimeric toxin: an intramolecular location for the insertion of transforming growth factor α within Pseudomonas exotoxin as a targeting ligand. Bioconjug. Chem. 3:1992;58-62.
329. Kreitman R.J., Siegall C.B., Chaudhary V.K., FitzGerald D.J., Pastan I. Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor α at different locations in Pseudomonas exotoxin. Bioconjug. Chem. 3:1992;63-68.
330. Theuer C.P., FitzGerald D.J., Pastan I. A recombinant form of Pseudomonas exotoxin A containing transforming growth factor alpha nears its carboxyl terminus for the treatment of bladder cancer. J. Urol. 149:1993;1626-1632.
331. Debinski W., Siegall C.B., FitzGerald D., Pastan I. Substitution of foreign protein sequences into a chimeric toxin composed of transforming growth factor α and Pseudomonas exotoxin. Mol. Cell. Biol. 11:1991;1751-1753.
332. 389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J. Biol. Chem. 266:1991;21118-21124.
333. Lorimer I.A., Keppler-Hafkemeyer A., Beers R.A., Pegram C.N., Bigner D.D., Pastan I. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc. Natl. Acad. Sci. USA. 93:1996;14815-14820.
334. Lorimer I.A.J., Wikstrand C.J., Batra S.K., Bigner D.D., Pastan I. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin. Cancer Res. 1:1995;859-864.
335. Mesri E.A., Kreitman R.J., Fu Y.-m., Epstein S.E., Pastan I. Heparin-binding transforming growth factor α-Pseudomonas exotoxin A. J. Biol. Chem. 268:1993;4853-4862.
336. Mesri E.A., Ono M., Kreitman R.J., Klagsbrun M., Pastan I. The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans. J. Cell. Sci. 107:1994;2599-2608.
337. Fu Y.-m., Mesri E.A., Yu Z.-x., Kreitman R.J., Pastan I., Epstein S.E. Cytotoxic effects on vascular smooth muscle cells of the chimeric toxin heparin binding TGFα-Pseudomonas exotoxin. Cardiovasc. Res. 27:1993;1691-1697.
338. Batra J.K., Kasprzyk P.G., Bird R.E., Pastan I., King C.R. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA. 89:1992;5867-5871.
339. Reiter Y., Brinkmann U., Jung S., Lee B., Kasprzyk P.G., King C.R., Pastan I. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J. Biol. Chem. 269:1994;18327-18331.
340. Wels W., Harwerth I.-m., Mueller M., Groner B., Hynes N.E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res. 52:1992;6310-6317.
341. Wels W., Moritz D., Schmidt M., Jeschke M., Hynes N.E., Groner B. Biotechnological and gene therapeutic strategies in cancer treatment. Gene. 159:1995;73-80.
342. Jeschke M., Wels W., Dengler W., Imber R., Stocklin E., Groner B. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins. Int. J. Cancer. 60:1995;730-739.
343. Schmidt M., Wels W. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha. Br. J. Cancer. 74:1996;853-862.
344. Schmidt M., Hynes N.E., Groner B., Wels W. A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor. Int. J. Cancer. 65:1996;538-546.
345. Pastan I., Lovelace E.T., Gallo M.G., Rutherford A.V., Magnani J.L., Willingham M.C. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res. 51:1991;3781-3787.
346. Pai L.H., Batra J.K., FitzGerald D.J., Willingham M.C., Pastan I. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys. Cancer Res. 52:1992;3189-3193.
347. Pastan I.H., Archer G.E., McLendon R.E., Friedman H.S., Fuchs H.E., Wang Q.C., Pai L.H., Herndon J., Bigner D.D. Intrathecal administration of single-chain immunotoxin, LMB-7 (B3(Fv)-PE38), produces cures of carcinomatous meningitis in a rat model. Proc. Natl. Acad. Sci. USA. 92:1995;2765-2769.
348. Pai L.H., Batra J.K., FitzGerald D.J., Willingham M.C., Pastan I. Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin (published erratum appears in Proc Natl Acad Sci USA 1991 Jun 1;88(11):5066). Proc. Natl. Acad. Sci. USA. 88:1991;3358-3362.
349. Pai L.H., Wittes R., Setser A., Willingham M.C., Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nature Med. 2:1996;350-353.
350. Brinkmann U., Pai L.H., FitzGerald D.J., Willingham M., Pastan I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl. Acad. Sci. USA. 88:1991;8616-8620.
351. 2, and Fab′ conjugated to Pseudomonas exotoxin. Bioconjug. Chem. 3:1992;302-307.
352. Friedman P.N., McAndrew S.J., Gawlak S.L., Chace D., Trail P.A., Brown J.P., Siegall C.B. BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells. Cancer Res. 53:1993;334-339.
353. Siegall C.B., Chace D., Mixan B., Garrigues U., Wan H., Paul L., Wolff E., Hellstrom I., Hellstrom K.E. In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats. J. Immunol. 152:1994;2377-2384.
354. Friedman P.N., Chace D.F., Trail P.A., Siegall C.B. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts. J. Immunol. 150:1993;3054-3061.
355. Siegall C.B., Liggitt D., Chace D., Tepper M.A., Fell H.P. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proc. Natl. Acad. Sci. USA. 91:1994;9514-9518.
356. Y damaged human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. Clin. Cancer Res. 1:1995;1589-1594.
357. Benhar I., Pastan I. Cloning, expression and characterization of the Fv fragments of the anti-carbohydrate mAbs B1 and B5 as single-chain immunotoxins. Protein Eng. 7:1994;1509-1515.
358. Benhar I., Padlan E.A., Jung S., Lee B., Pastan I. Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38. Proc. Natl. Acad. Sci. USA. 91:1994;12051-12055.
359. Benhar I., Pastan I. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice. Clin. Cancer Res. 1:1995;1023-1029.
360. Benhar I., Reiter Y., Pai L.H., Pastan I. Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice. Int. J. Cancer. 62:1995;351-355.
361. Siegall C.B., Epstein S., Speir E., Hla T., Forough R., Maciag T., FitzGerald D.J., Pastan I. Cytotoxic activity of chimeric proteins composed of acidic fibroblast growth factor and Pseudomonas exotoxin on a variety of cell types. FASEB J. 5:1991;2843-2849.
362. Siegall C.B., Gawlak S.L., Chace D.F., Merwin J.R., Pastan I. In vivo activities of acidic fibroblast growth factor-Pseudomonas exotoxin fusion proteins. Bioconjug. Chem. 5:1994;77-83.
363. Biro S., Siegall C.B., Fu Y.M., Speir E., Pastan I., Epstein S.E. In vitro effects of a recombinant toxin targeted to the fibroblast growth factor receptor on rat vascular smooth muscle and endothelial cells. Circ. Res. 71:1992;640-645.
364. Gawlak S.L., Pastan I., Siegall C.B. Basic fibroblast growth factor-Pseudomonas exotoxin chimeric proteins; comparison with acidic fibroblast growth factor-Pseudomonas exotoxin. Bioconjug. Chem. 4:1993;483-489.
365. Davol P., Frackelton A.R. Jr. The mitotoxin, basic fibroblast growth factor-saporin, effectively targets human prostatic carcinoma in an animal model. J. Urol. 156:1996;1174-1179.
366. Davol P., Beitz J.G., Mohler M., Ying W., Cook J., Lappi D.A., Frackelton A.R. Jr. Saporin toxins directed to basic fibroblast growth factor receptors effectively target human ovarian teratocarcinoma in an animal model. Cancer. 76:1995;79-85.
367. Batoz M., Coll Fresno P.M., Pizette S., Raffioni S., Birnbaum D., Coulier F. A diphtheria toxin/fibroblast growth factor 6 mitotoxin selectively kills fibroblast growth factor receptor-expressing cell lines. Cell. Growth. Differ. 6:1995;1143-1149.
368. CollFresno P.M., Batoz M., Tarquin S., Birnbaum D., Coulier F. Cytotoxic activity of a diphtheria toxin/FGF6 mitotoxin on human tumour cell lines. Oncogene. 14:1997;243-247.
369. Murphy J.R., Bishai W., Borowski M., Miyanohara A., Boyd J., Nagle S. Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related α-melanocyte-stimulating hormone fusion protein. Proc. Natl. Acad. Sci. USA. 83:1986;8258-8262.
370. Tatro J.B., Wen Z., Entwistle M.L., Atkins M.B., Smith T.J., Reichlin S., Murphy J.R. Interaction of an alpha-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastases. Cancer Res. 52:1992;2545-2548.
371. Prior T.I., Helman L.J., FitzGerald D.J., Pastan I. Cytotoxic activity of a recombinant fusion protein between insulin-like growth factor I and Pseudomonas exotoxin. Cancer Res. 51:1991;174-180.
372. Cavallaro U., Soria M.R. Targeting plant toxins to the urokinase and alpha 2-macroglobulin receptors. Semin. Cancer Biol. 6:1995;269-278.
373. Cavallaro U., del Vecchio A., Lappi D.A., Soria M.R. A conjugate between human urokinase and saporin, a type-1 ribosome-inactivating protein, is selectively cytotoxic to urokinase receptor-expressing cells. J. Biol. Chem. 268:1993;23186-23190.
374. Negro A., Skaper S.D. Production, characterization and cytotoxic properties of a diphtheria toxin-ciliary neurotrophic factor fusion protein. Protein Eng. 8:1995;175-183.
375. Negro A., Skaper S.D. Synthesis, cytotoxic properties and effects on early and late gene induction of a chimeric diphtheria toxin-leukemia-inhibitory factor protein. Eur. J. Biochem. 241:1996;507-515.
376. Debinski W., Miner R., Leland P., Obiri N.I., Puri R.K. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J. Biol. Chem. 271:1996;22428-22433.
377. Puri R.K., Leland P., Obiri N.I., Husain S.R., Kreitman R.J., Haas G.P., Pastan I., Debinski W. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood. 87:1996;4333-4339.
378. Debinski W., Obiri N.I., Pastan I., Puri R.K. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. Biol. Chem. 270:1995;16775-16780.
379. Ramakrishnan S., Olson T.A., Bautch V.L., Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res. 56:1996;1324-1330.
380. Schmidberger H., King L., Lasky L.C., Vallera D.A. Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo. Cancer Res. 50:1990;3249-3256.
381. Derbyshire E.J., Henry R.V., Stahel R.A., Wawrzynczak E.J. Potent cytotoxic action of the immunotoxin SWA11-ricin A chain against human small cell lung cancer cell lines. Br. J. Cancer. 66:1992;444-451.
382. Wawrzynczak E.J., Derbyshire E.J., Henry R.V., Parnell G.D., Smith A., Waibel R., Stahel R.A. Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen. Br. J. Cancer. 62:1990;410-414.
383. Derbyshire E.J., Stahel R.A., Wawrzynczak E.J. Cytotoxic properties of a ricin A chain immunotoxin recognising the cluster-5A antigen associated with human small-cell lung cancer. Cancer Immunol. Immunother. 35:1992;417-420.
384. Wawrzynczak E.J., Derbyshire E.J., Henry R.V., Parnell G.D., Smith A., Waibel R., Stahel R.A. Cytotoxic activity of ricin A chain immunotoxins recognising cluster 1, w4 and 5A antigens associated with human small cell lung cancer. Br. J. Cancer Suppl. 14:1991;71-73.
385. Zangemeister-Wittke U., Collinson A.R., Fisch I., Jones R.M., Waibel R., Lehman H.P., Stahel R.A. Anti-tumor activity of a blocked ricin immunotoxin with specificity against the cluster-5A antigen associated with human small-cell lung cancer. Int. J. Cancer. 54:1993;1028-1035.
386. Derbyshire E.J., Wawrzynczak E.J. An anti-mucin immunotoxin BrE-3-ricin A-chain is potently and selectively toxic to human small-cell lung cancer. Int. J. Cancer. 52:1992;624-630.
387. Derbyshire E.J., Stahel R.A., Wawrzynczak E.J. Potentiation of a weakly active ricin A chain immunotoxin recognizing the neural cell adhesion molecule. Clin. Exp. Immunol. 89:1992;336-340.
388. Roy D.C., Ouellet S., Le Houillier C., Ariniello P.D., Perreault C., Lambert J.M. Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin. J. Natl. Cancer Inst. 88:1996;1136-1145.
389. Lynch T.J. Immunotoxin therapy of small-cell lung cancer. N901-blocked ricin for relapsed small-cell lung cancer. Chest. 103:1993;436s-439s.
390. Lynch T.J., Lambert J.M., Coral F., Shefner J., Wen P., Blattler W.A., Collinson A.R., Ariniello P.D., Braman G., Cook S., Esseltine D., Elias A., Skarin A., Ritz J. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J. Clin. Oncol. 15:1997;723-734.
391. Epstein C., Lynch T., Shefner J., Wen P., Maxted D., Braman V., Ariniello P., Coral F., Ritz J. Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. Int. J. Cancer Suppl. 8:1994;57-59.
392. Spitler L.E., Rio M.d., Khentigan A., Wedel N.I., Brophy N.A., Miller L.L., Harkonen W.S., Rosendorf L.L., Lee H.M., Mischak R.P., Kawahata R.T., Stoudemire J.B., Fradkin L.B., Bautista E.E., Scannon P.J. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res. 47:1987;1717-1723.
393. Selvaggi K., Saria E.A., Schwartz R., Vlock D.R., Ackerman S., Wedel N., Kirkwood J.M., Jones H., Ernstoff M.S. Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. J. Immunother. 13:1993;201-207.
394. Oratz R., Speyer J.L., Wernz J.C., Hochster H., Meyers M., Mischak R., Spitler L.E. Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial. J. Biol. Response Mod. 9:1990;345-354.
395. Mujoo K., Cheung L., Murray J.L., Rosenblum M.G. Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin. Cancer Immunol. Immunother. 40:1995;339-345.
396. Rosenblum M.G., Murray J.L., Cheung L., Rifkin R., Salmon S., Bartholomew R. A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin. Mol. Biother. 3:1991;6-13.
397. Mujoo K., Reisfeld R.A., Cheung L., Rosenblum M.G. A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2. Cancer Immunol. Immunother. 34:1991;198-204.
398. Gilliland D.G., Steplewski Z., Collier R.J., Mitchell K.F., Chang T.H., Koprowski H. Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc. Natl. Acad. Sci. USA. 77:1980;4539-4543.
399. Byers V.S., Pimm M.V., Pawluczyk I.Z.A., Lee H.M., Scannon P.J., Baldwin R.W. Biodistribution of ricin toxin A chain-monoclonal antibody 791T/36 immunotoxin and influence of hepatic blocking agents. Cancer Res. 47:1987;5277-5283.
400. Byers V.S., Pimm M.V., Scannon P.J., Pawluczyk I., Baldwin R.W. Inhibition of growth of human tumor xenografts in athymic mice treated with ricin toxin A chain-monoclonal antibody 791T/36 conjugates. Cancer Res. 47:1987;5042-5046.
401. Embleton M.J., Byers V.S., Lee H.M., Scannon P., Blackhall N.W., Baldwin R.W. Sensitivity and selectivity of ricin toxin A chain-monoclonal antibody 791T/36 conjugates against human tumor cell lines. Cancer Res. 46:1986;5524-5528.
402. Byers V.S., Rodvien R., Grant K., Durrant L.G., Hudson K.H., Baldwin R.W., Scannon P.J. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer. Cancer Res. 49:1989;6153-6160.
403. Durrant L.G., Byers V.S., Scannon P.J., Rodvien R., Grant K., Robins R.A., Marksman R.A., Baldwin R.W. Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients. Clin. Exp. Immunol. 75:1989;258-264.
404. Levin L.V., Griffin T.W., Childs L.R., Davis S., Haagensen D.E. Jr. Comparison of multiple anti-CEA immunotoxins active against human adenocarcinoma cells. Cancer Immunol. Immunother. 24:1987;202-206.
405. Ito T., Qiu H., Collins J.A., Brill A.B., Johnson D.K., Griffin T.W. Preclinical assessments of 90Y-labeled C110 anti-carcinoembryonic antigen immunotoxin: a therapeutic immunoconjugate for human colon cancer. Cancer Res. 51:1991;255-260.
406. Debinski W., Pastan I. Recombinant F(ab′) C242-Pseudomonas exotoxin, but not the whole antibody-based immunotoxin, causes regression of a human colorectal tumor xenograft. Clin. Cancer Res. 1:1995;1015-1022.
407. Debinski W., Karlsson B., Lindholm L., Siegall C.B., Willingham M.C., FitzGerald D., Pastan I. Monoclonal antibody C242-Pseudomonas exotoxin A. A specific and potent immunotoxin with antitumor activity on a human colon cancer xenograft in nude mice. J. Clin. Invest. 90:1992;405-411.
408. Calvete J.A., Newell D.R., Wright A.F., Rose M.S. In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer. Cancer Res. 54:1994;4684-4690.
409. Westwood F.R., Jones D.V., Aldridge A. The synovial membrane, liver, and tongue: target organs for a ricin A-chain immunotoxin (ZD0490). Toxicol. Pathol. 24:1996;477-483.
410. Reiter Y., Wright A.F., Tonge D.W., Pastan I. Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice. Int. J. Cancer. 67:1996;113-123.
411. Krolick K.A., Yuan D., Vitetta E.S. Specific killing of a breast carcinoma cell line by a monoclonal antibody coupled to the A-chain of ricin. Cancer Immunol. Immunother. 12:1981;39-41.
412. Pirker R., FitzGerald D.J., Hamilton T.C., Ozols R.F., Laird W., Frankel A.E., Willingham M.C., Pastan I. Characterization of immunotoxins active against ovarian cancer cell lines. J. Clin. Invest. 76:1985;1261-1267.
413. Gould B.J., Borowitz M.J., Groves E.S., Carter P.W., Anthony D., Weiner L.M., Frankel A.E. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J. Natl. Cancer Inst. 81:1989;775-781.
414. Weiner L.M., O'Dwyer J., Kitson J., Comis R.L., Frankel A.E., Bauer R.J., Konrad M.S., Groves E.S. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res. 49:1989;4062-4067.
415. Fulcher S., Foulks G.N., Wilkerson M., Cobo L.M., Houston L.L., Hatchell D. Suppression of human corneal epithelial proliferation with breast carcinoma immunotoxin. Cornea. 12:1993;391-396.
416. Rosenblum M.G., Zuckerman J.E., Marks J.W., Rotbein J., Allen W.R. A gelonin-containing immunotoxin directed against human breast carcinoma. Mol. Biother. 4:1992;122-129.
417. FitzGerald D.J., Willingham M.C., Cardarelli C.O., Hamada H., Tsuruo T., Gottesman M.M., Pastan I. A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc. Natl. Acad. Sci. USA. 84:1987;4288-4292.
418. Mickisch G.H., Pai L.H., Siegsmund M., Campain J., Gottesman M.M., Pastan I. Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal carcinomas and in MDR-transgenic mice. J. Urol. 149:1993;174-178.
419. r 170 000 glycoprotein and a saporin-conjugated anti-mouse antibody. Cancer Res. 50:1990;4291-4294.
420. Thiesen H.J., Juhl H., Arndt R. Selective killing of human bladder cancer cells by combined treatment with A and B chain ricin antibody conjugates. Cancer Res. 47:1987;419-423.
421. Battelli M.G., Polito L., Bolognesi A., Lafleur L., Fradet Y., Stirpe F. Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line. Int. J. Cancer. 65:1996;485-490.
422. Willingham M.C., FitzGerald D.J., Pastan I. Pseudomonas exotoxin coupled to a monoclonal antibody against ovarian cancer inhibits the growth of human ovarian cancer cells in a mouse model. Proc. Natl. Acad. Sci. USA. 84:1987;2474-2478.
423. Pearson J.W., FitzGerald D.J., Willingham M.C., Wiltrout R.H., Pastan I., Longo D.L. Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice. Cancer Res. 49:1989;3562-3567.
424. Pai L.H., Bookman M.A., Ozols R.F., Young R.C., Smith J.W., Longo D.L., Frankel A., McClay E.F., Howell S., Reed E., Willingham M.C., FitzGerald D.J., Pastan I. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J. Clin. Oncol. 9:1991;2095-2103.
425. Brinkmann U., Gallo M., Brinkmann E., Kunwar S., Pastan I. A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA. 90:1993;547-551.
426. Anderson P.M., Meyers D.E., Hasz D.E., Covalcuic K., Saltzman D., Khanna C., Uckun F.M. In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein. Cancer Res. 55:1995;1321-1327.
427. Kaneta Y., Tsukazaki K., Kubushiro K., Aoki R., Sakayori M., Ueda M., Nozawa S. Effects of gelonin immunoconjugate of monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vitro. Oncol. Rep. 4:1997;331-336.
428. Burrows F.J., Thorpe P.E. Vascular targeting - a new approach to the therapy of solid tumors. Pharmac. Ther. 64:1994;155-174.
429. Burrows F.J., Thorpe P.E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl. Acad. Sci. USA. 90:1993;8996-9000.
430. Huang X.M., Molema G., King S., Watkins L., Edgington T.S., Thorpe P.E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 275:1997;547-550.